Literature DB >> 30282710

Engineered Small-Molecule Control of Influenza A Virus Replication.

Elizabeth J Fay1,2, Stephanie L Aron2,3, Ian A Stone2,3, Barbara M Waring2,3, Richard K Plemper4, Ryan A Langlois5,2,3.   

Abstract

Influenza A virus (IAV) remains a global health concern despite the availability of a seasonal vaccine. It is difficult to predict which strains will circulate during influenza season, and therefore, it is extremely challenging to test novel vaccines in the human population. To overcome this obstacle, new vaccines must be tested in challenge studies. This approach poses significant safety problems, since current pharmacological interventions for IAV are poorly efficacious. New methods are needed to enhance the safety of these challenge studies. In this study, we have generated a virus expressing a small-molecule-assisted shutoff (SMASh) tag as a safety switch for IAV replication. The addition of the SMASh tag to an essential IAV protein allows for small-molecule-mediated inhibition of replication. Treatment with this drug controls the replication of a SMASh-tagged virus in vitro and in vivo This model for restriction of viral replication has potential for broad applications in vaccine studies, virotherapy, and basic virus research.IMPORTANCE Influenza A virus (IAV) causes significant morbidity and mortality annually worldwide, despite the availability of new formulations of the vaccine each season. There is a critical need to develop more-efficacious vaccines. However, testing novel vaccines in the human population in controlled studies is difficult due to the limited availability and efficacy of intervention strategies should the vaccine fail. There are also significant safety concerns for work with highly pathogenic IAV strains in the laboratory. Therefore, novel strategies are needed to improve the safety of vaccine studies and of research on highly pathogenic IAV. In this study, we developed an IAV strain engineered to contain a small-molecule-mediated safety switch. This tag, when attached to an essential viral protein, allows for the regulation of IAV replication in vitro and in vivo This strategy provides a platform for the regulation of virus replication without targeting viral proteins directly.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  biotechnology; influenza vaccines; virus engineering

Mesh:

Substances:

Year:  2018        PMID: 30282710      PMCID: PMC6288343          DOI: 10.1128/JVI.01677-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Authors:  Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

2.  Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses.

Authors:  Ryan A Langlois; Andrew Varble; Mark A Chua; Adolfo García-Sastre; Benjamin R tenOever
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 3.  Investigating influenza A virus infection: tools to track infection and limit tropism.

Authors:  Jessica K Fiege; Ryan A Langlois
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

Review 4.  The role of viral, host, and secondary bacterial factors in influenza pathogenesis.

Authors:  John C Kash; Jeffery K Taubenberger
Journal:  Am J Pathol       Date:  2015-03-05       Impact factor: 4.307

5.  MicroRNA-Based Attenuation of Influenza Virus across Susceptible Hosts.

Authors:  Louisa E Sjaastad; Jessica K Fiege; Barbara M Waring; Elizabeth J Fay; Ismarc Reyes; Branden Moriarity; Ryan A Langlois
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

6.  Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection.

Authors:  Suzanne E Ohmit; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Arnold S Monto
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

7.  Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

Authors:  Fiona McPhee; Amy K Sheaffer; Jacques Friborg; Dennis Hernandez; Paul Falk; Guangzhi Zhai; Steven Levine; Susan Chaniewski; Fei Yu; Diana Barry; Chaoqun Chen; Min S Lee; Kathy Mosure; Li-Qiang Sun; Michael Sinz; Nicholas A Meanwell; Richard J Colonno; Jay Knipe; Paul Scola
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

8.  The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit.

Authors:  Alexandre Dias; Denis Bouvier; Thibaut Crépin; Andrew A McCarthy; Darren J Hart; Florence Baudin; Stephen Cusack; Rob W H Ruigrok
Journal:  Nature       Date:  2009-02-04       Impact factor: 49.962

9.  Hepatitis C virus NS3-4A inhibits the peroxisomal MAVS-dependent antiviral signalling response.

Authors:  Ana R Ferreira; Ana C Magalhães; Fátima Camões; Ana Gouveia; Marta Vieira; Jonathan C Kagan; Daniela Ribeiro
Journal:  J Cell Mol Med       Date:  2016-02-10       Impact factor: 5.310

10.  Tunable and reversible drug control of protein production via a self-excising degron.

Authors:  Hokyung K Chung; Conor L Jacobs; Yunwen Huo; Jin Yang; Stefanie A Krumm; Richard K Plemper; Roger Y Tsien; Michael Z Lin
Journal:  Nat Chem Biol       Date:  2015-07-27       Impact factor: 15.040

View more
  6 in total

Review 1.  On the cutting edge: protease-based methods for sensing and controlling cell biology.

Authors:  H Kay Chung; Michael Z Lin
Journal:  Nat Methods       Date:  2020-07-13       Impact factor: 28.547

2.  A degron system targeting endogenous PD-1 inhibits the growth of tumor cells in mice.

Authors:  Chie Naruse; Kazushi Sugihara; Tatsuhiko Miyazaki; Xuchi Pan; Fumihiro Sugiyama; Masahide Asano
Journal:  NAR Cancer       Date:  2022-06-17

Review 3.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

4.  Long-term surviving influenza infected cells evade CD8+ T cell mediated clearance.

Authors:  Jessica K Fiege; Ian A Stone; Rebekah E Dumm; Barbara M Waring; Brian T Fife; Judith Agudo; Brian D Brown; Nicholas S Heaton; Ryan A Langlois
Journal:  PLoS Pathog       Date:  2019-09-26       Impact factor: 6.823

5.  Influenza virus replication in cardiomyocytes drives heart dysfunction and fibrosis.

Authors:  Adam D Kenney; Stephanie L Aron; Clara Gilbert; Naresh Kumar; Peng Chen; Adrian Eddy; Lizhi Zhang; Ashley Zani; Nahara Vargas-Maldonado; Samuel Speaks; Jeffrey Kawahara; Parker J Denz; Lisa Dorn; Federica Accornero; Jianjie Ma; Hua Zhu; Murugesan V S Rajaram; Chuanxi Cai; Ryan A Langlois; Jacob S Yount
Journal:  Sci Adv       Date:  2022-05-11       Impact factor: 14.957

6.  Cell type- and replication stage-specific influenza virus responses in vivo.

Authors:  Elizabeth J Fay; Stephanie L Aron; Marissa G Macchietto; Matthew W Markman; Katharina Esser-Nobis; Michael Gale; Steven Shen; Ryan A Langlois
Journal:  PLoS Pathog       Date:  2020-08-13       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.